11/30
08:52 am
atra
Atara Biotherapeutics: An Empty Pipeline With Little Gas [Seeking Alpha]
High
Report
Atara Biotherapeutics: An Empty Pipeline With Little Gas [Seeking Alpha]
11/14
01:10 pm
atra
Atara Biotherapeutics (NASDAQ:ATRA) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Atara Biotherapeutics (NASDAQ:ATRA) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
11/12
09:17 am
atra
Atara Biotherapeutics: Q3 Earnings Snapshot [Yahoo! Finance]
Low
Report
Atara Biotherapeutics: Q3 Earnings Snapshot [Yahoo! Finance]
11/12
09:00 am
atra
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
Low
Report
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
11/9
01:10 am
atra
Atara Biotherapeutics (NASDAQ:ATRA) was downgraded by analysts at
Weiss Ratings from a "hold (c-)" rating to a "sell (d+)" rating.
Low
Report
Atara Biotherapeutics (NASDAQ:ATRA) was downgraded by analysts at
Weiss Ratings from a "hold (c-)" rating to a "sell (d+)" rating.
11/3
09:00 am
atra
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
Medium
Report
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
10/24
12:16 pm
atra
Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by analysts at
Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
Low
Report
Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by analysts at
Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
10/3
03:30 pm
atra
Atara Biotherapeutics (NASDAQ:ATRA) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Atara Biotherapeutics (NASDAQ:ATRA) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.